GlassScriptPhysician profile
Ryan Molter Jones
NPI 1720426760
$1,002.84
in general payments reported to CMS, 2019-2025
23 companies · $529 in 2025
The $529 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $81.18 · 2021: $157 · 2022: $14.84 · 2023: $23.80 · 2024: $197 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726 · Education: $23.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.07 |
| Education | $23.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $111.97 | 2020-2025 | Xpovio |
| Exelixis INC. | $93.47 | 2020-2025 | Cabometyx |
| Abbvie INC. | $79.79 | 2020-2025 | |
| Incyte Corporation | $77.92 | 2021-2025 | Jakafi, Niktimvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.57 | 2021-2025 | |
| Genmab U.S., INC. | $65.53 | 2025 | Epkinly |
| Gilead Sciences, INC. | $61.95 | 2024-2025 | Trodelvy |
| Sobi, INC | $54.70 | 2024-2025 | |
| Celgene Corporation | $52.95 | 2021-2025 | Opdivo |
| Beigene USA, INC. | $48.40 | 2020-2024 | Tevimbra |
| Merck Sharp & Dohme LLC | $40.31 | 2021-2025 | Lynparza, Keytruda |
| Astrazeneca Pharmaceuticals LP | $34.42 | 2020-2021 | |
| Daiichi Sankyo INC. | $28.66 | 2021-2022 | |
| Geron Corporation | $26.36 | 2025 | Rytelo |
| Genzyme Corporation | $26.35 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fennec Pharmaceuticals, INC. | $24.68 | 2025 | Fyarro |
| Beone Medicines USA, INC. | $22.02 | 2025 | Tevimbra |
| Aveo Pharmaceuticals, INC. | $19.44 | 2025 | |
| Btg International INC. | $19.17 | 2025 | Voraxaze |
| Glaxosmithkline, LLC. | $16.33 | 2021 | |
| Emd Serono, INC. | $16.32 | 2021 | |
| Stemline Therapeutics INC. | $15.53 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.